. 2018 Apr 12;4(4):260–267. doi: 10.1016/j.cdtm.2017.11.002

Table 1.

Main characteristics of the selected studies.

Study	Study design	Period	Population	AMI at admission	PLVAD				IABP
Study	Study design	Period	Population	AMI at admission	n	Mean Age (years)	Baseline LVEF (%)	Device	n	Mean Age (years)	Baseline LVEF (%)
Reddy et al (2014)¹¹	Obs. Multicenter	March. 2006–December. 2011	High-risk VT	No	44	66 ± 12	29 ± 15	TandemHeart or Impella	22	69 ± 10	25 ± 10
Shah et al (2012)¹²	Obs. Single-center	March. 2007–December. 2009	High-risk PCI	No	22	69 ± 9	28 ± 11	TandemHeart or Impella	35	60 ± 9.9	33 ± 13
Shah et al (2012)¹²	Obs. Single-center	March. 2007–December. 2009	Cardiogenic shock	No	4	68 ± 13	13 ± 2.9	TandemHeart or Impella	13	57 ± 12	30 ± 13
O'Neill et al (2012)¹³	RCT. Multicenter	November. 2007–December. 2010	High-risk PCI	No	225	68 ± 11	23.4 ± 6.3	Impella	223	67 ± 11	24.1 ± 6.3
Seyfarth et al (2008)¹⁴	RCT. Two-center	September. 2004–January. 2007	Cardiogenic shock	Yes	13	65 (57–71)	27(20–39)	Impella	13	67(55–80)	28(23–44)
Burkhoff et al (2006)¹⁵	RCT. Multicenter	April. 2002–April. 2004	Cardiogenic shock	Yes	19	66 ± 14	19 ± 14	TandemHeart	14	60 ± 11	21 ± 7
Thiele et al (2005)¹⁶	RCT. Single-center	August. 2000–December. 2003	Cardiogenic shock	Yes	21	63 (57–70)	25.0 (20.0–32.8)	TandemHeart	20	65(59–73)	28.5(20.5–30.5)

PLVAD: percutaneous left ventricular assist device; IABP: intra-aortic balloon pump; MACCE: major adverse cardiac and cardiovascular events; Obs: observational study; RCT: randomized controlled trial; VT: ventricular tachycardia; PCI: percutaneous coronary intervention; LVEF: left ventricular ejection fraction; MI: myocardial infarction.